Contract Deobligations Alert — March 13, 2026

VA awards total $1.65B across 5 contracts for medical evaluations, IT, and insurance, with high outlays ($1.3B disbursed) signaling immediate revenue for TriWest, Veterans Evaluation, Cognosante, Technatomy, and Richard Group.

$980M HHS/BARDA obligations to Advanced Technology Intl ($795M) and MAPP Biopharma ($185M) for biotech R&D through 2029+, with $101M outlayed indicating committed viral therapeutics funding.

L3Harris ($814M NASA space to 2029), Lockheed Martin ($65M DHS C4ISR/sustainment to 2026), and Boeing sub Insitu ($96M UAS) provide $975M multi-year backlog in aerospace/engineering services.

$942M GSA/VA/DHS IT delivery orders (e.g., Salient CRGT $422M DEA, ThirdPacket $64M CMS) through 2028 offer $700M+ in options upside.

Firm fixed price dominates 9/15 contracts ($3.9B value), exposing winners to cost overruns amid long periods (avg. 4+ years to 2029+).

Low/no outlays on $2.5B (50%) including top awards (TriWest $0, BL Harbert $0) signal cash flow delays despite future starts.

Heavy subawards ($470M+ across contracts) create subcontractor dependencies, especially L3Harris (538 subs $169M).

$1.7B+ in unobligated options (e.g., Salient $454M, MAPP $722M, Cognosante $241M) across 8 contracts could double values through 2028-2032.

Set-aside wins for veteran/8(a)/small disadvantaged firms ($431M) signal pipeline for VA/HHS/DHS follow-ons.

Nonprofit/small biz neutral signals ($952M) indicate stable funding flows to biotech/IT without equity dilution risks.

VA/HHS dominate 56% ($2.8B) in medical/IT/R&D, with $2B+ through 2029 targeting evaluations, EHR, and biotech.

$1.7B to primes/subs (L3Harris, Lockheed, Boeing) averaging 7-year terms underscores stable backlog amid tech risks.

$1B+ in competed IT awards (GSA/VA/CMS) with $700M options highlight DevSecOps and app dev demand.

{"entity"=>"TriWest Healthcare Alliance", "reason"=>"$820M VA award is largest single obligation but 1-month Feb 2026 window with $0 outlay raises execution flags.", "trigger"=>"outlay initiation or modification by Q2 2026"}

{"entity"=>"L3Harris Technologies", "reason"=>"$814M NASA to 2029 with $216M outlayed but high subawards/tech risks in space instruments.", "trigger"=>"option funding or subaward delays"}

{"entity"=>"BL Harbert International", "reason"=>"$814M State construction non-competitive to 2029 with $0 outlay; firm fixed price exposure.", "trigger"=>"funding release or cost overrun signals"}

{"entity"=>"Salient CRGT", "reason"=>"$422M obligated + $454M options for DEA IT to 2028 positions for major upside.", "trigger"=>"option exercises expanding to $876M ceiling"}

{"entity"=>"HHS/BARDA Biotech Awards", "reason"=>"$980M R&D pipeline through 2030+ amid viral threat focus.", "trigger"=>"new task orders or commercial spinouts"}